Major diseases among the cadres were cataract(47.58%),prostatic hypertrophy(46.28%),hypertension(38.38%),hyperlipoidemia(32.17%),fatty liver(25.70%),coronary heart disease(21.88%),diabetes mellitus(11.99%),and gallstone(7.77%).
The serum LH, FSH, PRL and plasma T, E_2 and E_2/T ratio were assessed before and after prostatectomy in 23 patients with benigh prostatic hypertrophy at 60-80 years of age. It was found that after operation the LH, FSH, T, E_2 and E_2/T ratio had a tendency to decrease and PRL a tendency to increase.
Plasma testosterone (T), estradiol(E_2) and E_2/T ratio were determined in ten patients who had benign prostatic hypertrophy (BPH), and compared with those in ten cases who were senile male with non-prostatic hypertrophy (NPH).
Results The ADC of lymph nodes was significantly greater in patients with benign prostate hyperplasia [(2.282±0.573)×10-3 mm2/s] than that with prostate cancer [(1.607±0.256)×10-3 mm2/s)](P=0.000).
Clinical significance of F/T PSA in differential diagnosis of benign prostate hyperplasia and prostate cancer with TPSA values between 4. 0 and 10. 0 μg/L
RESULTS: Rates of heterozygote of IGF-Ⅱ DNA were 70.7% (29/41) in prostate cancer group, 55.5% (15/27) in benign prostate hyperplasia group, and 61.5% (8/13) in normal prostate tissue group.
Routine transurethral resection was performed due to benign prostatic hyperplasia with subvesical obstruction.
GYKI-16084 - (+)-(R)-2-{3-(benzo[1,4]dioxan-2-yl-methylamino)-1-propyl}-3(2H)-pyridazinone hydrochloride - is a new drug candidate for the treatment of benign prostatic hyperplasia.
Minimally invasive techniques for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: An up
Benign prostatic hyperplasia (BPH) primarily affects middle-aged and elderly men.
Urinary incontinence can result following surgical treatment of benign prostatic hyperplasia or prostate cancer and has a significant impact on quality of life.
Routine transurethral resection was performed due to benign prostatic hyperplasia with subvesical obstruction.
GYKI-16084 - (+)-(R)-2-{3-(benzo[1,4]dioxan-2-yl-methylamino)-1-propyl}-3(2H)-pyridazinone hydrochloride - is a new drug candidate for the treatment of benign prostatic hyperplasia.
Minimally invasive techniques for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: An up
Benign prostatic hyperplasia (BPH) primarily affects middle-aged and elderly men.
Urinary incontinence can result following surgical treatment of benign prostatic hyperplasia or prostate cancer and has a significant impact on quality of life.
Hedgehog signaling in prostate growth and benign prostate hyperplasia
This review examines the role of Hh signaling during early prostate growth and in its corollary actions during prostate disease, including benign prostate hyperplasia and prostate cancer.
Management of lower urinary tract symptoms resulting from benign prostate hyperplasia in the high-risk surgical patient presents a unique challenge.
Hedgehog signaling in prostate growth and benign prostate hyperplasia
This review examines the role of Hh signaling during early prostate growth and in its corollary actions during prostate disease, including benign prostate hyperplasia and prostate cancer.